EUCTR2004-001461-18-ITActive, not recruitingNot Applicable
A 20 week multi-national, open-labelled, randomised, three-group parallel trial comparing administration of insulin detemir morning, insulin detemir evening and NPH insulin evening as add-on to oral antidiabetic drug(s) in subjects with type 2 diabetes
OVO NORDISK0 sitesStarted: March 4, 2005Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Active, not recruiting
Phase 1
A 20 week multi-national, open-labelled, randomised, three-group parallel trial comparing administration of insulin detemir morning, insulin detemir evening and NPH insulin evening as add-on to oral antidiabetic drug(s) in subjects with type 2 diabetesMedDRA version: 7.0Level: PTClassification code 10049746Type 2 DiabetesEUCTR2004-001461-18-ESovo Nordisk AS
Completed
Phase 4
Comparison of biphasic insulin aspart 30 individually adjusted by the subject and the trial physician, respectively, both combined with metformin in subjects with type 2 diabetesCTRI/2011/12/002241ovo Nordisk India Private Limited91
Active, not recruiting
Not Applicable
A 20 weeks randomised, multinational, open labelled,2 parallel group comparison of biphasic insulin aspart (BIAsp) 30 in combination with metformin in subjects with type 2 diabetes, which is inadequately controlled on basal insulin analogues. One treatment group use twice daily titration of biphasic insulin aspart 30 driven by the subject, the other group use twice daily titration of biphasic insulin aspart 30 driven by the investigator. Both groups combine their treatment with metformin.Type 2 diabetesMedDRA version: 14.0Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2010-024303-27-GBovo Nordisk A/S338
Active, not recruiting
Not Applicable
A 20 weeks randomised, multinational, open labelled,2 parallel group comparison of biphasic insulin aspart (BIAsp) 30 in combination with metformin in subjects with type 2 diabetes, which is inadequately controlled on basal insulin analogues. One treatment group use twice daily titration of biphasic insulin aspart 30 driven by the subject, the other group use twice daily titration of biphasic insulin aspart 30 driven by the investigator. Both groups combine their treatment with metformin.Type 2 diabetesMedDRA version: 14.0Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2010-024303-27-PLovo Nordisk A/S338
Completed
Phase 4
Effect of insulin detemir and insulin glargine on blood glucose control in subjects with type 2 diabetesCTRI/2009/091/000161ovo Nordisk AS52